rs786204583
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PM1PM2PM5PP3_StrongPP5_Very_Strong
The NM_014625.4(NPHS2):c.502C>T(p.Arg168Cys) variant causes a missense change. The variant allele was found at a frequency of 0.00000208 in 1,439,948 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R168H) has been classified as Likely pathogenic.
Frequency
Consequence
NM_014625.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
NPHS2 | NM_014625.4 | c.502C>T | p.Arg168Cys | missense_variant | 4/8 | ENST00000367615.9 | NP_055440.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
NPHS2 | ENST00000367615.9 | c.502C>T | p.Arg168Cys | missense_variant | 4/8 | 1 | NM_014625.4 | ENSP00000356587.4 | ||
NPHS2 | ENST00000367616.4 | c.502C>T | p.Arg168Cys | missense_variant | 4/7 | 1 | ENSP00000356588.4 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 0.00000208 AC: 3AN: 1439948Hom.: 0 Cov.: 30 AF XY: 0.00000140 AC XY: 1AN XY: 714140
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Nephrotic syndrome, type 2 Pathogenic:5
Likely pathogenic, criteria provided, single submitter | clinical testing | Juno Genomics, Hangzhou Juno Genomics, Inc | - | PM2_Supporting+PP3_Strong+PP4 - |
Likely pathogenic, criteria provided, single submitter | literature only | Counsyl | Sep 02, 2014 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Dr.Nikuei Genetic Center | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Nov 17, 2023 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Apr 11, 2023 | - - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 04, 2023 | This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 168 of the NPHS2 protein (p.Arg168Cys). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with nephrotic syndrome (PMID: 15253708, 30721404, 32604935). ClinVar contains an entry for this variant (Variation ID: 188952). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt NPHS2 protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects NPHS2 function (PMID: 14675423). This variant disrupts the p.Arg168 amino acid residue in NPHS2. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 14675423, 15042551, 15059485, 26467726, 28385484). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at